Lee P. Shulman

Lee P. Shulman is a Professor of Obstetrics and Gynecology (Clinical Genetics) at Northwestern University's Feinberg School of Medicine and Adjunct Professor at the University of Illinois at Chicago College of Pharmacy. He serves as Medical Director of Insight Medical Genetics and Reproductive Genetics Innovations and Treasurer of the International Society for Prenatal Diagnosis.

Dr. Shulman earned his MD from Cornell University Medical College (1983) with postgraduate training including Obstetrics/Gynecology internship at North Shore University Hospital (1984), residency at North Shore University Hospital, New York (1987), and Reproductive Genetics fellowship at the University of Tennessee Medical Center (1989).

• Board Certified in Clinical Genetics (American Board of Medical Genetics and Genomics)
• Board Certified in Obstetrics and Gynecology (American Board of Obstetrics and Gynecology)

His research spans reproductive/cancer genetics, contraception, menopause, women's healthcare advocacy, and botanical interventions in women's health. With over 200 peer-reviewed articles and 60 book chapters, his work advances genetic counseling and personalized medicine for women.

Recent publications address folic acid deficiency prevention, COVID-19 treatments in pregnancy, and dydrogesterone pharmacovigilance, highlighting his focus on bridging clinical practice with reproductive genetics research.

Consistently ranked Top Doctor in Chicago (2007-2022) and nationally (2005-2022), recent accolades include:

• Visiting Professor, Memphis Ob/Gyn Society (2024)
• Dr. Kermit E. Krantz Memorial Paper (2024)
• Invited Professor, Israel Society of Contraception (2024)
• America's Most Honored Doctors (2023)

Dr. Shulman leads significant advisory roles including Chief Dysmorphologist for Pregistry, scientific advisory boards for Shield Therapeutics and Juniper Genomics, and former Board Examiner for the American Board of Obstetrics and Gynecology.

He directs Insight Medical Genetics and leads the Northwestern Ovarian Cancer Early Detection and Prevention Program clinical trial focused on improving early detection strategies for high-risk populations.